{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T20:25:17Z","timestamp":1788639917578,"version":"build-2803163510"},"reference-count":19,"publisher":"The Journal of Rheumatology","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Rheumatol"],"published-print":{"date-parts":[[2012,8]]},"abstract":"<jats:sec>\n                    <jats:title>Objective.<\/jats:title>\n                    <jats:p>In patients with systemic lupus erythematosus (SLE), evidence suggests that most vaccines (except live-virus vaccines) are safe, although antibody response may be reduced. This substudy from the phase III, randomized, double-blind, placebo-controlled BLISS-76 trial evaluated the effects of belimumab on preexisting antibody levels against pneumococcal, tetanus, and influenza antigens in patients with SLE.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods.<\/jats:title>\n                    <jats:p>In BLISS-76, patients with autoantibody-positive, active SLE were treated with placebo or belimumab 1 or 10 mg\/kg every 2 weeks for 28 days and every 28 days thereafter, plus standard SLE therapy, for 76 weeks. This analysis included a subset of patients who had received pneumococcal or tetanus vaccine within 5 years or influenza vaccine within 1 year of study participation. Antibodies to vaccine antigens were tested at baseline and Week 52, and percentage changes in antibody levels from baseline and proportions of patients maintaining levels at Week 52 were assessed. Antibody titers were also assessed in a small number of patients vaccinated during the study.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results.<\/jats:title>\n                    <jats:p>Consistent with preservation of the memory B cell compartment with belimumab treatment, the proportions of patients maintaining antibody responses to pneumococcal, tetanus, and influenza antigens were not reduced. In a small group receiving influenza vaccine on study, antibody responses were frequently lower with belimumab, although titer levels were &gt; 1:10 in all patients treated with 10 mg\/kg and in the majority treated with 1 mg\/kg.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion.<\/jats:title>\n                    <jats:p>\n                      Treatment with belimumab did not affect the ability of patients with SLE to maintain antibody titers to previous pneumococcal, tetanus, and influenza immunizations. [\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"ClinicalTrials.gov\" ext-link-type=\"uri\" xlink:type=\"simple\">ClinicalTrials.gov<\/jats:ext-link>\n                      registration number NCT 00410384]\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3899\/jrheum.111587","type":"journal-article","created":{"date-parts":[[2012,6,17]],"date-time":"2012-06-17T17:21:49Z","timestamp":1339953709000},"page":"1632-1640","source":"Crossref","is-referenced-by-count":85,"title":["Effect of Belimumab on Vaccine Antigen Antibodies to Influenza, Pneumococcal, and Tetanus Vaccines in Patients with Systemic Lupus Erythematosus in the BLISS-76 Trial"],"prefix":"10.3899","volume":"39","author":[{"given":"W. WINN","family":"CHATHAM","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"DANIEL J.","family":"WALLACE","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"WILLIAM","family":"STOHL","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"KEVIN M.","family":"LATINIS","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"SUSAN","family":"MANZI","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W. JOSEPH","family":"McCUNE","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"DANA","family":"TEGZOV\u00c1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"JAMES D.","family":"McKAY","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"HILARIO E.","family":"AVILA-ARMENGOL","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"TAMMY O.","family":"UTSET","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Z. JOHN","family":"ZHONG","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"DOUGLAS R.","family":"HOUGH","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"WILLIAM W.","family":"FREIMUTH","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"THI-SAU","family":"MIGONE","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2262","published-online":{"date-parts":[[2012,6,15]]},"reference":[{"key":"2018112909280733000_39.8.1632.1","doi-asserted-by":"publisher","DOI":"10.1177\/0961203306069355"},{"key":"2018112909280733000_39.8.1632.2","doi-asserted-by":"publisher","DOI":"10.1002\/art.30576"},{"key":"2018112909280733000_39.8.1632.3","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)61354-2"},{"key":"2018112909280733000_39.8.1632.4","doi-asserted-by":"publisher","DOI":"10.1002\/art.30613"},{"key":"2018112909280733000_39.8.1632.5","doi-asserted-by":"publisher","DOI":"10.1084\/jem.192.7.953"},{"key":"2018112909280733000_39.8.1632.6","doi-asserted-by":"publisher","DOI":"10.1016\/S0960-9822(01)00598-X"},{"key":"2018112909280733000_39.8.1632.7","doi-asserted-by":"publisher","DOI":"10.1126\/science.285.5425.260"},{"key":"2018112909280733000_39.8.1632.8","doi-asserted-by":"publisher","DOI":"10.1002\/art.11299"},{"key":"2018112909280733000_39.8.1632.9","doi-asserted-by":"crossref","unstructured":"Stohl W Hiepe F Latinis KM Thomas M Scheinberg MA Clarke A Belimumab reduces autoantibodies, normalizes low complement, and reduces select B-cell populations in patients with systemic lupus erythematosus. Arthritis Rheum 2012 Jan 24 (E-pub ahead of print).","DOI":"10.1002\/art.34400"},{"key":"2018112909280733000_39.8.1632.10","unstructured":"Galazka AM . The immunological basis for immunization series. Module 3: Tetanus. Geneva: World Health Organization; 1993. [Internet. Accessed May 3, 2012.] Available from: http:\/\/www.who.int\/vaccines-documents\/DocsPDF-IBI-e\/mod3_e.pdf"},{"key":"2018112909280733000_39.8.1632.11","unstructured":"World Health Organization . Immunizations, vaccines and biologicals: Pneumococcal vaccines. 2003. [Internet. Accessed May 3, 2012.] Available from: http:\/\/www.who.int\/vaccines\/en\/pneumococcus.shtml"},{"key":"2018112909280733000_39.8.1632.12","unstructured":"World Health Organization . Initiative for vaccine research (IVR). Acute respiratory infections. Influenza. 2009. [Internet. Accessed May 3, 2012.] Available from: http:\/\/www.who.int\/vaccine_research\/diseases\/ari\/en\/index1.htmlresearch\/diseases\/ari\/en\/index1.html"},{"key":"2018112909280733000_39.8.1632.13","first-page":"97","article-title":"Immune correlates of protection against influenza in the human challenge model","volume":"115","author":"Treanor","year":"2003","journal-title":"Dev Bio"},{"key":"2018112909280733000_39.8.1632.14","doi-asserted-by":"publisher","DOI":"10.1002\/art.24699"},{"key":"2018112909280733000_39.8.1632.15","first-page":"1","article-title":"Prevention of pneumococcal disease: Recommendations of the Advisory Committee on Immunization Practices (ACIP)","volume":"46","year":"1997","journal-title":"Morb Mortal Wkly Rep"},{"key":"2018112909280733000_39.8.1632.16","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2010.12.072"},{"key":"2018112909280733000_39.8.1632.17","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2008.12.002"},{"key":"2018112909280733000_39.8.1632.18","doi-asserted-by":"publisher","DOI":"10.1186\/ar3047"},{"key":"2018112909280733000_39.8.1632.19","doi-asserted-by":"publisher","DOI":"10.1002\/art.25033"}],"container-title":["The Journal of Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.3899\/jrheum.111587","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,11,29]],"date-time":"2018-11-29T13:17:02Z","timestamp":1543497422000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jrheum.org\/lookup\/doi\/10.3899\/jrheum.111587"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,6,15]]},"references-count":19,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2012,8,1]]},"published-print":{"date-parts":[[2012,8]]}},"alternative-id":["10.3899\/jrheum.111587"],"URL":"https:\/\/doi.org\/10.3899\/jrheum.111587","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.717948951.793454523","asserted-by":"object"},{"id-type":"doi","id":"10.3410\/f.717948951.793454053","asserted-by":"object"},{"id-type":"doi","id":"10.3410\/f.717948951.793455903","asserted-by":"object"}]},"ISSN":["0315-162X","1499-2752"],"issn-type":[{"value":"0315-162X","type":"print"},{"value":"1499-2752","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,6,15]]}}}